Treatment for ischemic stroke: From thrombolysis to thrombectomy and remaining challenges
- PMID: 31001594
- PMCID: PMC6458775
- DOI: 10.4103/bc.bc_36_18
Treatment for ischemic stroke: From thrombolysis to thrombectomy and remaining challenges
Abstract
Stroke is a leading cause of death and long-term disabilities. Despite decades of extensive efforts in search of brain injury mechanisms and therapeutic interventions, pharmacological treatment is limited to the use of thrombolytic agent tissue plasminogen activator, which has limited therapeutic time window and potential side effect of intracranial hemorrhage. Over the past few years, endovascular thrombectomy with stent-retriever devices combined with advanced imaging modalities has transformed the standard of stroke care, offering an opportunity to improve the outcome in selected patients as late as 24 h after the onset of stroke. This mini-review summarizes the advancement in the treatment of ischemic stroke, from thrombolysis to thrombectomy and remaining challenges in the field.
Keywords: Stroke; thrombectomy; thrombolysis; tissue plasminogen activator.
Conflict of interest statement
There are no conflicts of interest.
References
-
- Kochanek KD, Murphy S, Xu J, Arias E. Mortality in the United States, 2016. NCHS Data Brief. 2017;293:1–8. - PubMed
-
- Romero JM, Rosand J. Hemorrhagic cerebrovascular disease. Handb Clin Neurol. 2016;135:351–64. - PubMed
-
- Sembill JA, Huttner HB, Kuramatsu JB. Impact of recent studies for the treatment of intracerebral hemorrhage. Curr Neurol Neurosci Rep. 2018;18:71. - PubMed
-
- Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial – Italy (MAST-I) Group. Lancet. 1995;346:1509–14. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
